Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy, being developed for treatment of adults with unresectable/metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naïve to peptide receptor radionuclide therapy.
Lead Product(s): Alphamedix
Therapeutic Area: Oncology Product Name: AlphaMedix
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: RadioMedix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
NVL-655 is a novel brain-penetrant ALK-selective tyrosine kinase inhibitor. It is being developed for the treatment of ALK-positive non-small cell lung cancer and other solid tumors.
Lead Product(s): NVL-655
Therapeutic Area: Oncology Product Name: NVL-655
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Under the terms of the collaboration, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Recipient: Orbit Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 11, 2023
Details:
AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitting particles.
Lead Product(s): Alphamedix
Therapeutic Area: Oncology Product Name: AlphaMedix
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: RadioMedix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
212Pb-DOTAM-G is a 212Pb-conjugated anti-GRPR (Gastrin-Releasing Peptide Receptor) targeting different types of solid tumors including several breast and prostate cancers tumor types.
Lead Product(s): ²¹²Pb-DOTAM-GRPR1
Therapeutic Area: Oncology Product Name: ²¹²Pb-DOTAM-GRPR1
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023